Annual report
8086.TEDINET S100YJLK
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥660.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥644.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥586.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥545.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥37.6bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥26.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥19.7bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥19.5bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥15.3bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥29.5bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥19.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥13.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.1bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.6bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥15.7bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥6.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥1.21T | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.11T | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.03T | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥930.3bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥878.5bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥858.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥334.8bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥311.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥269.8bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥242.2bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥199.9bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥97.8bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥106.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥88.4bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥101.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥96.6bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥84.7bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥90.1bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥54.7bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥72.9bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥55.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥71.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥87.1bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥71.7bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥8.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥22.1bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥43.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥82.8 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.36 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.12 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.05 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥73.36 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥60.35 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.85 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,680.71 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,547.82 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,426.56 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,265 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,135.76 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 22.6% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.0% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.1% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 38,593 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 39,168 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 38,117 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 38,770 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 36,259 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥414.7bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥393.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥368.3bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥349.7bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥331.2bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥15.1bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥8.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥15.6bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥9.7bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥19.3bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥22.3bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥13.5bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥18.8bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥6.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥8.7bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.7bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥844.6bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥825.7bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥808.6bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥764.9bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥727.0bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥636.7bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥629.9bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥208.0bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥195.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥187.5bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥181.6bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥179.7bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥17.5bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥22.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥82.57 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.54 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.1 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.47 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.87 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥73.16 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥102.37 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥37.3 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥47.38 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥61.82 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥29 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥22 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥27 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,275.07 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,200.51 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,149.68 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,113.64 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,102.07 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 24.6% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.2% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.7% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.8% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 171,459,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,714 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 4,563 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 4,388 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 4,390 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 4,252 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 103
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2025-04-01 → 2026-03-31 | ¥362m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2025-04-01 → 2026-03-31 | ¥674m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-03-31 | 159 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2026-03-31 | ¥7.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥6.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2026-03-31 | ¥273.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2026-03-31 | ¥940m |
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥4.3bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥81.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥81.2bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | −¥232.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥26.2bn |
| Medical Treatment Relatedreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥35.6bn |
| Medical Treatment Relatedreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥36.7bn |
| Medical Treatment Relatedreportable segment | employees | at 2026-03-31 | 27089 pure |
| Medical Treatment Relatedreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥530.9bn |
| Medical Treatment Relatedreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥523.6bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥7.3bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2026-03-31 | ¥779.0bn |
| Medical Treatment Relatedreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥52.3bn |
| Medicine Relatedreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥25.9bn |
| Medicine Relatedreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥14.5bn |
| Medicine Relatedreportable segment | employees | at 2026-03-31 | 8271 pure |
| Medicine Relatedreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥141.7bn |
| Medicine Relatedreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥81.1bn |
| Medicine Relatedreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥60.6bn |
| Medicine Relatedreportable segment | segment assets | at 2026-03-31 | ¥277.2bn |
| Medicine Relatedreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥12.1bn |
| Pharma Packagingreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥6.4bn |
| Pharma Packagingreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥5.4bn |
| Pharma Packagingreportable segment | employees | at 2026-03-31 | 2183 pure |
| Pharma Packagingreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥62.0bn |
| Pharma Packagingreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥54.7bn |
| Pharma Packagingreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥7.3bn |
| Pharma Packagingreportable segment | segment assets | at 2026-03-31 | ¥116.0bn |
| Pharma Packagingreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥1.6bn |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥67.9bn |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥56.7bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥734.6bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥659.4bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥75.2bn |
| —segment total | segment assets | at 2026-03-31 | ¥1.17T |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥62.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥68.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥57.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥741.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥660.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥81.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥1.45T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥63.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥525m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥250.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥245m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥7.5bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥83.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥83.8bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥171.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥30.6bn |
| Medical Treatment Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥41.5bn |
| Medical Treatment Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥34.8bn |
| Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥512.0bn |
| Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥505.1bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.9bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2025-03-31 | ¥711.9bn |
| Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥46.6bn |
| Medicine Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥19.8bn |
| Medicine Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥15.3bn |
| Medicine Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥143.0bn |
| Medicine Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥79.1bn |
| Medicine Relatedreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥63.8bn |
| Medicine Relatedreportable segment | segment assets | at 2025-03-31 | ¥266.4bn |
| Medicine Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥10.6bn |
| Pharma Packagingreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥11.7bn |
| Pharma Packagingreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Pharma Packagingreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥66.1bn |
| Pharma Packagingreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥59.3bn |
| Pharma Packagingreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.8bn |
| Pharma Packagingreportable segment | segment assets | at 2025-03-31 | ¥113.4bn |
| Pharma Packagingreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥272m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥73.0bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥57.4bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥721.1bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥643.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥77.6bn |
| —segment total | segment assets | at 2025-03-31 | ¥1.09T |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥57.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥74.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥57.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥728.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥644.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥83.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.34T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥57.2bn |
| Medical Treatment Relatedreportable segment | employees | at 2026-03-31 | 3613 pure |
| Medicine Relatedreportable segment | employees | at 2026-03-31 | 38 pure |
| Pharma Packagingreportable segment | employees | at 2026-03-31 | 172 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,141
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)㈱メディパルホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)(保有目的)医療用医薬品の取引先であり、取引関係を維持・強化させるため保有しています。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)クオールホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)(保有目的)医療用医薬品の取引先であり、取引関係を維持・強化させるため保有しています。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)㈱あいちフィナンシャルグループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)無(注)３ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)わかもと製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)(保有目的) 医療用医薬品の取引先であり、取引関係を維持・強化させるため保有しています。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)第一生命ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)(保有目的)保険取引を通じて、良好な取引関係を維持・強化させるため保有しています。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)無(注)４ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)㈱みずほフィナンシャルグループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)無(注)５ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | Original text (Japanese)レンゴー㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row14Member | Original text (Japanese)㈱モリタホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row14Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row14Member | Original text (Japanese)有 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row3Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row4Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row5Member | Text · Plus | |
| Basic policy on human resources strategy employees etc (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)ニプロファーマ㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | Original text (Japanese)ニプロ医工㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | Original text (Japanese)㈱グッドマン | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | Original text (Japanese)全星薬品工業㈱ | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Changes in scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and reasons for exclusion from scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |